There was no statistical significance in BM rates of stage I and II patients between EGFR mutation-positive adenocarcinoma and EGFR mutation-negative adenocarcinoma (stage I, 1.8% (5/275) vs. 0.9% (3/335); stage II, 3.6% (1/28) vs. 6.9% (3/58)). This evidence concerns the gene EGFR and adenocarcinoma.